Conference Paper

Abstract Newly diagnosed GBM patients experience challenges to maintain their health related QoL throughout the disease course. Disease- and treatment-related factors impact health related QoL. We sought to evaluate the trajectory of health related QoL in newly diagnosed glioblastoma patients treated with bevacizumab at diagnosis, through the disease course, and beyond progression. In this prospective single-center study, newly diagnosed subjects with GBM were treated with concurrent radiation and temozolomide plus bevacizumab followed by adjuvant temozolomide and bevacizumab. At progression, bevacizumab use was continued but chemotherapy could be changed per the treating neuro-oncologist recommendation. Health related QoL was evaluated using the Functional Assessment of Cancer Therapy-Brain (FACT-Br) at time of study enrollment (before chemoradiation), after chemoradiation, and then every 6 mos until study discontinuation or subject demise. Higher scores on the FACT-Br correspond to better QoL. 68 newly diagnosed GBM patients were enrolled with a mean age of 55.4 yrs (sd=10.7 yrs). KPS ranged 70-100 with the following distribution: 70 (n=4), 80 (n=28), 90 (n=34), and 100 (n=2). FACT-Br scores were relatively maintained from baseline evaluation (mean=96.71, sd=17.64) to 20 months from baseline (mean=100.68, sd=22.12). Subjects who continued study participation 6 mos after the completion of chemoradiation were divided into two groups: subjects with (n=16) and without (n=35) tumor progression 6 mos after chemoradiation completion. Regardless of disease progression, both groups maintained QoL (with progression baseline (mean=98.06, sd=17.18) and 14 months from baseline (mean=91.80, sd 7.16) and without progression baseline (mean=96.34 sd=17.09) and 14 months from baseline (mean=96.75, sd=24.95)). Our observations of health related QoL throughout the disease course and beyond progression suggest that health related QoL can be maintained in GBM patients treated with bevacizumab. Continued evaluation of health related QoL throughout the disease course is warranted in the evaluation of novel treatment regimens in GBM.

Full Text

Cited Authors

  • Peters, KB; Affronti, ML; Threatt, S; Healy, P; Herndon, JE; Lipp, ES; Panta, S; Randazzo, D; Friedman, HS; Desjardins, A

Duke Contributors

Published Date

  • November 6, 2017

Published In

Volume / Issue

  • 19 / suppl_6

Start / End Page

  • vi206 - vi206

Published By

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

International Standard Serial Number (ISSN)

  • 1522-8517

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nox168.832

Conference Name

  • 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Conference Location

  • San Francisco, CA

Conference Start Date

  • November 16, 2017

Conference End Date

  • November 19, 2017